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Background
The design of an optimal highly active antiretroviral
therapy (HAART) customised on patient’sb a c k g r o u n d
and viral genotyping, is still a challenge. EuResist has
been the first data-driven system to be implemented as
a free web-service for customised HAART optimisation,
and was proven to be superior to all existing genotypic
interpretation systems (GIS) since it takes into account
not only genotype but multiple other variables.
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The EuResist database stores and updates periodically
demographic, clinical, and genomic information of HIV
+ patients from several countries in Western Europe.
The EuResist system is trained on treatment change epi-
sodes (TCE) drawn from the EuResist data base, com-
posed of a new drug regimen with a baseline HIV-1
RNA load and a CD4+ count, a baseline viral pol geno-
type, demographic and previous treatment information.
Each TCE is associated to an HIV-1 RNA measurement
after 8 weeks, which is used for the definition of virolo-
gical success (below 500 copies/ml or >2 Log10 reduc-
tion from baseline HIV-1 RNA). The system is a
combination of three independent machine learning
models (based on logistic regression, random forests,
and Bayesian networks). The 2010 update has been
trained on >5,000 TCE, composed of 20 FDA/EMEA
approved nucleoside/tide, non-nucleoside, and protease
inhibitors, including the recently approved compounds
(RAC) tipranavir, etravirine and darunavir.
Results
The EuResist combined system performance in predict-
ing the correct virological success of a TCE after 8-
weeks (validation set, n=561) exhibited an area under
the receiver operating characteristic (AUROC) of 0.8
(whereas Stanford HIVdb GIS assessed to 0.73,
p=0.002). The inclusion of therapy history, clinical, and
demographic covariates was shown to increase signifi-
cantly prediction performance. In the subset of regimens
containing RAC (n=151), the EuResist AUROC was 0.7
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assess a significant difference owing to the small sample
size. See Figure 1.
Conclusions
Based on patient’s information and virus genotype, the
EuResist web-service ranks the most effective HAART
regimens by the probability to achieve an undetectable
HIV-1 RNA load after 8 weeks. Thus, it might be useful
in clinical practice. The 2010 update includes also RAC
and achieved fair performance, which is expected to
increase with expanding training data.
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